Outcome Measures
SECONDARY
The primary outcome measure is the change from baseline in fasting TG levels after 6 weeks of xuezhikang (1.2 g/day) and pravastatin (20 mg/day). The secondary outcome measures are change from baseline after 6 weeks of treatment in other fasting lipid indexes (including total cholesterol, LDL-C, HDL-C, non-HDL-C, remnant cholesterol, Lp(a), apolipoprotein [Apo] A1, and ApoB), change from baseline in postprandial TG levels 1, 2, or 4 h after breakfast, fasting, and postprandial plasma glucose and insulin levels, fasting HbA1c level, and change from baseline after 6 weeks in fasting and postprandial levels of high-sensitivity C-reactive protein. An overview of the assessments is provided in Table 